“The company delivered strong quarterly results due to recovering treatment volumes in the US market, prompting management to upgrade its outlook. Strategic divestments of non-core Latin American assets and supportive US regulatory payment increases are expected to drive further growth.”
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.